Insider Selling: Arcus Biosciences (NYSE:RCUS) CAO Sells 4,343 Shares of Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 4,343 shares of Arcus Biosciences stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $22.25, for a total transaction of $96,631.75. Following the sale, the chief accounting officer owned 18,531 shares of the company’s stock, valued at $412,314.75. The trade was a 18.99% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Alexander Azoy also recently made the following trade(s):

• On Wednesday, December 17th, Alexander Azoy sold 2,113 shares of Arcus Biosciences stock. The stock was sold at an average price of $22.16, for a total transaction of $46,824.08.
• On Tuesday, December 16th, Alexander Azoy sold 2,376 shares of Arcus Biosciences stock. The shares were sold at an average price of $21.88, for a total value of $51,986.88.
• On Wednesday, November 26th, Alexander Azoy sold 1,900 shares of Arcus Biosciences stock. The stock was sold at an average price of $26.00, for a total transaction of $49,400.00.
• On Monday, September 29th, Alexander Azoy sold 2,831 shares of Arcus Biosciences stock. The stock was sold at an average price of $13.00, for a total transaction of $36,803.00.

Arcus Biosciences Stock Down 1.2%

NYSE:RCUS traded down $0.26 during mid-day trading on Thursday, hitting $22.02. 1,175,874 shares of the company’s stock traded hands, compared to its average volume of 1,200,446. Arcus Biosciences, Inc. has a twelve month low of $6.50 and a twelve month high of $26.40. The company has a market capitalization of $2.38 billion, a P/E ratio of -6.40 and a beta of 0.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65. The company has a fifty day moving average of $20.82 and a 200 day moving average of $13.98.

Arcus Biosciences (NYSE:RCUS) last posted its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share for the quarter, beating the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative return on equity of 68.17% and a negative net margin of 136.40%.The business had revenue of $26.00 million for the quarter, compared to the consensus estimate of $19.89 million. During the same quarter in the previous year, the business earned ($1.00) EPS. The company’s quarterly revenue was down 45.8% compared to the same quarter last year. On average, analysts forecast that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Wall Street Analysts Forecast Growth

RCUS has been the topic of a number of recent analyst reports. HC Wainwright increased their price target on Arcus Biosciences from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, October 8th. Bank of America boosted their target price on shares of Arcus Biosciences from $17.00 to $26.00 and gave the company a “neutral” rating in a report on Friday, November 28th. Wall Street Zen raised Arcus Biosciences from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, Citigroup reiterated a “buy” rating on shares of Arcus Biosciences in a report on Friday, December 12th. Eight equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Arcus Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $28.89.

Institutional Trading of Arcus Biosciences

Several institutional investors and hedge funds have recently modified their holdings of RCUS. GAMMA Investing LLC increased its position in shares of Arcus Biosciences by 59.1% during the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock worth $37,000 after acquiring an additional 1,021 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Arcus Biosciences by 13,547.6% in the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. CWM LLC raised its stake in Arcus Biosciences by 233.6% during the 2nd quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares in the last quarter. Ameritas Investment Partners Inc. lifted its stake in shares of Arcus Biosciences by 34.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock worth $57,000 after acquiring an additional 1,796 shares during the period. Finally, PNC Financial Services Group Inc. grew its holdings in Arcus Biosciences by 440.3% during the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock worth $62,000 after acquiring an additional 6,191 shares during the period. Hedge funds and other institutional investors own 92.89% of the company’s stock.

About Arcus Biosciences

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.